VERU

Veru Inc.

Price Chart

Latest Quote

$3.13

+0.00 (+0.00%)

Current Price

Previous Close	$3.13
Open	$3.14
Day High	$3.20
Day Low	$2.96
Volume	686,822

Fetched: 2026-06-17T12:49:59

Stock Information

Shares Outstanding	16.05M
Total Debt	$2.83M
Cash Equivalents	$30.66M
Net Income	$-14.44M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$50.24M
EPS (TTM)	$-0.80
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$22.41M
Income	$-14.44M
Book/sh	$2.17
Cash/sh	$1.91
Employees	20

Financial Ratios

Quick Ratio	5.69
Current Ratio	6.19
Debt/Eq	8.14

Returns & Margins

ROA	-46.42%
ROE	-51.74%

Ownership

Insider Ownership	9.78%
Institutional Ownership	23.92%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-3.18
PEG	3.60
P/B	1.44

Analyst Data

Recommendation	strong_buy
Target Price	$24.50

Technical Indicators

SMA20	$2.72
SMA50	$2.48
SMA200	$2.73
RSI	59.17
ATR	0.6600

Shares Float	13.48M
Short Float	3.90%
Short Ratio	8.30
Volatility	-1.13
Rel Volume	0.12

Performance History

Week	+0.97%
Month	+48.34%
Quarter	+29.88%
6 Months	+29.34%
YTD	+37.89%
Year	-48.69%
3 Years	-76.11%
5 Years	-96.53%
10 Years	-77.15%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-16	$3.13	687,200
2026-06-15	$3.13	496,600
2026-06-12	$3.00	726,800
2026-06-11	$3.26	918,000
2026-06-10	$2.95	876,400
2026-06-09	$3.10	2,367,400
2026-06-08	$3.00	2,651,000
2026-06-05	$3.40	10,801,800
2026-06-04	$4.23	92,865,600
2026-06-03	$2.25	70,100
2026-06-02	$2.35	29,400
2026-06-01	$2.38	100,200
2026-05-29	$2.37	68,900
2026-05-28	$2.32	51,800
2026-05-27	$2.33	133,000
2026-05-26	$2.31	97,500
2026-05-22	$2.35	88,800
2026-05-21	$2.22	24,800
2026-05-20	$2.17	19,700
2026-05-19	$2.11	32,200
2026-05-18	$2.12	86,400

About Veru Inc.

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

📰 Latest News

Veru And 2 Other Intriguing Penny Stocks To Watch

Simply Wall St. • 2026-06-05T12:05:14Z

Novo Nordisk Tests Wegovy Combinations In Older Adults With Veru Trial

Simply Wall St. • 2026-06-05T06:09:13Z

This Small-Cap Biotech Just Soared Over 160% — What Is The Novo Nordisk Connection?

Stocktwits • 2026-06-04T17:16:12Z

Veru Teams Up With Novo Nordisk for Obesity Combination Therapy Trial (VERU)

InvestorsHub • 2026-06-04T14:22:56Z

Earnings call transcript: Veru Inc Q2 2026 shows improved financials

Stocktwits • 2026-06-01T04:11:24Z

Veru Inc (VERU) Q2 2026 Earnings Call Highlights: Promising Clinical Trial Results Amid ...

GuruFocus.com • 2026-05-13T23:03:24Z

Transcript: Veru Q2 2026 Earnings Conference Call

Benzinga • 2026-05-13T12:50:34Z

Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com • 2026-02-11T19:01:46Z

Veru Inc. Q1 2026 Earnings Call Summary

Moby • 2026-02-11T17:31:58Z

Veru (VERU) Q1 2026 Earnings Call Transcript

Motley Fool • 2026-02-11T13:53:42Z

Period:

Income Statement (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Revenue
Total Revenue	$0	$0	$16,296,958	$39,354,352
Operating Revenue	$0	$0	$16,296,958	$39,354,352
Reconciled Cost Of Revenue	-	$11,032,442	$8,731,030	$8,762,964
Cost Of Revenue	-	$11,032,442	$8,731,030	$8,762,964
Expenses
Total Expenses	$35,530,932	$37,391,968	$111,902,797	$122,842,510
Other Income Expense	$19,849,675	$2,132,030	$5,360,394	$4,052,735
Other Non Operating Income Expenses	$768,380	$1,085,199	$573,771	$495,735
Operating Expense	$35,530,932	$37,391,968	$103,171,767	$114,079,546
General And Administrative Expense	$19,942,747	$24,609,801	$48,057,834	$43,168,845
Interest Expense	-	$607,470	$2,427,041	$4,368,798
Net Non Operating Interest Income Expense	-	$-607,470	$-2,427,041	$-4,368,798
Interest Expense Non Operating	-	$607,470	$2,427,041	$4,368,798
Total Other Finance Cost	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-15,681,257	$-35,259,938	$-93,152,692	$-84,040,618
Normalized Income	$-34,762,552	$-36,306,769	$-96,934,124	$-86,850,648
Net Income From Continuing And Discontinued Operation	$-22,726,279	$-37,801,426	$-93,152,692	$-84,040,618
Total Operating Income As Reported	$-24,750,642	$-36,169,060	$-93,782,216	$-83,488,158
Net Income Common Stockholders	$-22,726,279	$-37,801,426	$-93,152,692	$-84,040,618
Net Income	$-22,726,279	$-37,801,426	$-93,152,692	$-84,040,618
Net Income Including Noncontrolling Interests	$-22,726,279	$-37,801,426	$-93,152,692	$-84,040,618
Net Income Discontinuous Operations	$-7,045,022	$-2,541,488	-	-
Net Income Continuous Operations	$-15,681,257	$-35,259,938	$-93,152,692	$-84,040,618
Pretax Income	$-15,681,257	$-35,259,938	$-92,672,486	$-83,804,221
Special Income Charges	$19,405,068	$1,222,908	$1,823,623	$0
Operating Income	$-35,530,932	$-37,391,968	$-95,605,839	$-83,488,158
Net Interest Income	-	$-607,470	$-2,427,041	$-4,368,798
Gross Profit	-	$5,853,977	$7,565,928	$30,591,388
Per Share
Diluted EPS	$-1.55	$-2.80	$-11.00	$-10.50
Basic EPS	$-1.55	$-2.80	$-11.00	$-10.50
Other
Tax Effect Of Unusual Items	$0	$0	$1,005,191	$746,970
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-54,460,122	$-38,170,622	$-94,762,194	$-82,782,828
Total Unusual Items	$19,081,295	$1,046,831	$4,786,623	$3,557,000
Total Unusual Items Excluding Goodwill	$19,081,295	$1,046,831	$4,786,623	$3,557,000
Reconciled Depreciation	$152,105	$268,177	$269,874	$209,595
EBITDA (Bullshit earnings)	$-35,378,827	$-37,123,791	$-89,975,571	$-79,225,828
EBIT	$-35,530,932	$-37,391,968	$-90,245,445	$-79,435,423
Diluted Average Shares	$14,646,294	$13,487,502	$8,497,338	$8,012,252
Basic Average Shares	$14,646,294	$13,487,502	$8,497,338	$8,012,252
Diluted NI Availto Com Stockholders	$-22,726,279	$-37,801,426	$-93,152,692	$-84,040,618
Gain On Sale Of Ppe	$10,780,290	$1,222,908	$5,723,623	$0
Other Special Charges	$-8,624,778	-	-	-
Gain On Sale Of Security	$-323,773	$-176,077	$2,963,000	$3,557,000
Research And Development	$15,588,185	$12,782,167	$51,202,219	$70,910,701
Selling General And Administration	$19,942,747	$24,609,801	$48,057,834	$43,177,345
Other Gand A	$19,942,747	$24,609,801	$48,057,834	$43,168,845
Tax Provision	-	$725,101	$480,206	$236,397
Impairment Of Capital Assets	-	$0	$3,900,000	$0
Provision For Doubtful Accounts	-	$0	$3,911,714	$-8,500
Gain On Sale Of Business	-	-	-	$0

Fetched: 2026-06-16

Balance Sheet (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Assets
Net Tangible Assets	$11,453,738	$25,437,780	$12,793,277	$71,941,004
Total Assets	$29,835,719	$60,418,772	$50,023,091	$135,358,450
Total Non Current Assets	$10,920,601	$25,195,548	$27,089,869	$31,356,543
Other Non Current Assets	$930,847	$14,584,621	$1,512,361	$1,561,564
Goodwill And Other Intangible Assets	$6,878,932	$6,878,932	$6,884,884	$10,856,313
Current Assets	$18,915,118	$35,223,224	$22,933,222	$104,001,907
Other Current Assets	$595,251	$805,633	$1,097,851	$1,964,373
Assets Held For Sale Current	$0	$8,759,011	-	-
Cash Cash Equivalents And Short Term Investments	$18,319,867	$25,658,580	$9,625,494	$80,190,675
Cash And Cash Equivalents	$15,794,562	$24,916,285	$9,625,494	$80,190,675
Non Current Deferred Assets	-	$12,340,237	$12,707,419	$12,965,985
Non Current Deferred Taxes Assets	-	$12,340,237	$12,707,419	$12,965,985
Prepaid Assets	-	$419,371	$1,006,252	$9,677,020
Inventory	-	$4,144,179	$6,697,117	$8,618,944
Receivables	-	$3,960,305	$4,506,508	$3,550,895
Accounts Receivable	-	$3,960,305	$4,506,508	$3,550,895
Allowance For Doubtful Accounts Receivable	-	$-3,937,434	$-3,938,862	$-24,997
Gross Accounts Receivable	-	$7,897,739	$8,445,370	$3,575,892
Other Intangible Assets	-	-	$5,952	$3,977,381
Notes Receivable	-	-	-	$0
Debt
Total Debt	$3,116,964	$13,518,908	$14,405,463	$15,876,288
Long Term Debt And Capital Lease Obligation	$2,358,018	$11,756,101	$12,504,250	$13,750,108
Current Debt And Capital Lease Obligation	$758,946	$1,762,807	$1,901,213	$2,126,180
Long Term Debt	-	$8,850,792	$8,870,136	$9,656,441
Current Debt	-	$1,025,837	$864,623	$1,169,095
Other Current Borrowings	-	$1,025,837	$864,623	$1,169,095
Net Debt	-	-	$109,265	-
Liabilities
Total Liabilities Net Minority Interest	$11,503,049	$28,102,060	$30,344,930	$52,561,133
Total Non Current Liabilities Net Minority Interest	$3,717,889	$16,234,092	$12,534,198	$13,849,752
Other Non Current Liabilities	$1,359,871	$4,461,920	$29,948	$18,577
Liabilities Heldfor Sale Non Current	$0	$16,071	-	-
Current Liabilities	$7,785,160	$11,867,968	$17,810,732	$38,711,381
Payables And Accrued Expenses	$3,515,977	$2,929,353	$14,918,910	$30,598,644
Payables	$3,121,448	$2,259,668	$12,931,172	$22,003,394
Accounts Payable	$3,121,448	$2,259,668	$12,931,172	$22,003,394
Other Current Liabilities	-	$2,681,530	-	-
Non Current Deferred Liabilities	-	-	$0	$81,067
Non Current Deferred Taxes Liabilities	-	-	$0	$81,067
Equity
Common Stock Equity	$18,332,670	$32,316,712	$19,678,161	$82,797,317
Total Equity Gross Minority Interest	$18,332,670	$32,316,712	$19,678,161	$82,797,317
Stockholders Equity	$18,332,670	$32,316,712	$19,678,161	$82,797,317
Gains Losses Not Affecting Retained Earnings	$0	$-581,519	$-581,519	$-581,519
Retained Earnings	$-317,295,914	$-294,569,635	$-256,768,209	$-163,615,517
Other Equity Adjustments	-	$-581,519	$-581,519	$-581,519
Other
Treasury Shares Number	$218,370	$218,370	$218,370	$218,370
Ordinary Shares Number	$14,650,320	$14,638,392	$9,178,269	$8,050,889
Share Issued	$14,868,690	$14,856,762	$9,396,639	$8,269,259
Tangible Book Value	$11,453,738	$25,437,780	$12,793,277	$71,941,004
Invested Capital	$18,332,670	$42,193,341	$29,412,920	$93,622,853
Working Capital	$11,129,958	$23,355,256	$5,122,490	$65,290,526
Capital Lease Obligations	$3,116,964	$3,642,279	$4,670,704	$5,050,752
Total Capitalization	$18,332,670	$41,167,504	$28,548,297	$92,453,758
Treasury Stock	$7,806,605	$7,806,605	$7,806,605	$7,806,605
Additional Paid In Capital	$343,286,502	$335,125,903	$283,894,830	$253,974,032
Capital Stock	$148,687	$148,568	$939,664	$826,926
Common Stock	$148,687	$148,568	$939,664	$826,926
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$2,358,018	$2,905,309	$3,634,114	$4,093,667
Current Capital Lease Obligation	$758,946	$736,970	$1,036,590	$957,085
Pensionand Other Post Retirement Benefit Plans Current	$3,510,237	$4,494,278	$990,609	$5,986,557
Current Accrued Expenses	$394,529	$669,685	$1,987,738	$8,595,250
Goodwill	$6,878,932	$6,878,932	$6,878,932	$6,878,932
Net PPE	$3,110,822	$3,731,995	$5,985,205	$5,972,681
Accumulated Depreciation	$-600,635	$-484,071	$-3,787,954	$-3,641,884
Gross PPE	$3,711,457	$4,216,066	$9,773,159	$9,614,565
Leases	$199,532	$199,532	$960,694	$484,460
Other Properties	$2,746,014	$3,250,623	$7,340,595	$7,689,630
Machinery Furniture Equipment	$765,911	$765,911	$1,471,870	$1,440,475
Properties	$0	$0	$0	$0
Other Short Term Investments	$2,525,305	$742,295	-	-
Inventories Adjustments Allowances	-	$-1,581,915	$-183,787	$-15,707
Finished Goods	-	$4,819,331	$4,913,295	$6,099,343
Work In Process	-	$79,181	$112,799	$872,596
Raw Materials	-	$827,582	$1,854,810	$1,662,712

Fetched: 2026-06-16

Cash Flow Statement (Annual)

Metric	2025-09-30	2024-09-30	2023-09-30	2022-09-30
Free Cash Flow
Free Cash Flow	$-30,044,171	$-21,840,655	$-88,679,514	$-48,238,056
Operating Activities
Operating Cash Flow	$-30,043,088	$-21,682,333	$-88,013,814	$-47,505,004
Cash Flow From Continuing Operating Activities	$-30,043,088	$-21,682,333	$-88,013,814	$-47,505,004
Operating Gains Losses	$-12,162,935	$-799,641	$-8,686,333	$-3,557,000
Investing Activities
Capital Expenditure	$-1,083	$-158,322	$-665,700	$-733,052
Investing Cash Flow	$25,142,976	$146,214	$6,334,300	$4,266,948
Cash Flow From Continuing Investing Activities	$25,142,976	$146,214	$6,334,300	$4,266,948
Net Other Investing Changes	$8,280,290	$304,536	$7,000,000	-
Capital Expenditure Reported	$-1,083	$-158,322	$-665,700	$-733,052
Financing Activities
Issuance Of Capital Stock	$0	$35,295,115	$6,009,366	$0
Financing Cash Flow	$-4,221,611	$36,826,910	$11,114,333	$1,069,196
Cash Flow From Continuing Financing Activities	$-4,221,611	$36,826,910	$11,114,333	$1,069,196
Net Other Financing Charges	$-4,221,611	$-132,975	$-130,782	-
Net Common Stock Issuance	$0	$35,295,115	$6,009,366	$0
Common Stock Issuance	$0	$35,295,115	$6,009,366	$0
Other
Interest Paid Supplemental Data	$332,826	$704,600	$554,818	$2,620,609
Income Tax Paid Supplemental Data	$78,548	$368,820	$247,361	$422,135
End Cash Position	$15,794,562	$24,916,285	$9,625,494	$80,190,675
Beginning Cash Position	$24,916,285	$9,625,494	$80,190,675	$122,359,535
Changes In Cash	$-9,121,723	$15,290,791	$-70,565,181	$-42,168,860
Proceeds From Stock Option Exercised	$0	$1,664,770	$5,235,749	$1,078,289
Net Investment Purchase And Sale	$393,217	$0	-	-
Sale Of Investment	$393,217	$0	-	-
Net Business Purchase And Sale	$16,470,552	$0	$0	$5,000,000
Sale Of Business	$16,470,552	$0	$0	$5,000,000
Change In Working Capital	$-4,128,891	$222,493	$-15,151,458	$26,146,561
Change In Other Current Liabilities	$-625,352	$-683,827	$-666,863	$-468,546
Change In Payables And Accrued Expense	$-4,107,787	$-1,488,030	$-20,790,141	$26,788,968
Change In Accrued Expense	$-1,347,500	$3,944,381	$-11,717,919	$8,195,345
Change In Payable	$-2,760,287	$-5,432,411	$-9,072,222	$18,593,623
Change In Account Payable	$-2,760,287	$-5,432,411	$-9,072,222	$18,593,623
Change In Prepaid Assets	$397,573	$862,039	$9,810,245	$-1,584,980
Change In Inventory	$863,928	$986,108	$648,628	$-3,126,710
Change In Receivables	$-657,253	$546,203	$-4,153,327	$4,537,829
Changes In Account Receivables	$-657,253	$546,203	$-4,153,327	$4,537,829
Other Non Cash Items	$471,709	$673,570	$2,613,480	$2,344,310
Stock Based Compensation	$8,102,177	$13,644,405	$17,918,603	$11,242,423
Unrealized Gain Loss On Investment Securities	$323,773	$176,077	$0	-
Provisionand Write Offof Assets	$-72,831	$1,566,830	$4,097,213	$73,519
Deferred Tax	$-1,916	$367,182	$177,499	$76,206
Deferred Income Tax	$-1,916	$367,182	$177,499	$76,206
Depreciation Amortization Depletion	$152,105	$268,177	$269,874	$209,595
Depreciation And Amortization	$152,105	$268,177	$269,874	$209,595
Gain Loss On Investment Securities	$3,138,316	$239,000	$-2,963,000	$-3,557,000
Gain Loss On Sale Of PPE	$0	$184,267	$290	-
Gain Loss On Sale Of Business	$4,103,817	$0	-	$0
Net Income From Continuing Operations	$-22,726,279	$-37,801,426	$-93,152,692	$-84,040,618
Asset Impairment Charge	-	$0	$3,900,000	$0
Repayment Of Debt	-	-	$0	$-9,093
Net Issuance Payments Of Debt	-	-	$0	$-9,093
Net Long Term Debt Issuance	-	-	$0	$-9,093
Long Term Debt Payments	-	-	$0	$-9,093

Fetched: 2026-06-16